Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer to Lead Pipeline Strategy
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the...
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the...
GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced...
Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced that...
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a global licensing and supply agreement with...
Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biopharmaceutical company, has announced a licensing and commercialization agreement...
Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou...
Sciwind Biosciences Co., Ltd, a China-based pharmaceutical company, has released the latest topline Phase III...
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...
InventisBio (Shanghai) Co., Ltd (SHA: 688382), a China-based pharmaceutical company, has announced that the New...
Frontage Laboratories Inc., (HKG: 1521), a Contract Research Organization (CRO) with operations in Pennsylvania, Suzhou,...
AstraZeneca (AZ, NASDAQ: AZN) and Sanofi (NASDAQ: SNY), co-development partners in the pharmaceutical industry, have...
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that its joint venture, PharmaGend...
Ascletis Pharma Inc. (HKG: 1672), a Chinese pharmaceutical company, has announced positive interim results from...
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
The National Medical Products Administration (NMPA) has granted separate approvals for two distinct drugs from...
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received approval...
The European Medicines Agency (EMA) has accepted for review a filing submitted by Bristol Myers...
Allorion Therapeutics, a China-based biopharmaceutical company, has announced an exclusive option and global licensing agreement...
Zhejiang Orient Gene Biotech Co., Ltd, a leading biotech company in China, is poised to...